CTP-543
Sponsors
Concert Pharmaceuticals, Sun Pharmaceutical Industries, Inc.
Conditions
Alopecia AreataHealth VolunteersHealthyHealthy VolunteersHepatic ImpairmentRenal Impairment
Phase 1
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects
CompletedNCT02777008
Start: 2016-05-31End: 2017-03-31Updated: 2017-03-13
Food Effect Study of CTP-543 in Healthy Volunteers
CompletedNCT03880136
Start: 2019-03-25End: 2019-04-05Updated: 2019-06-13
Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects
CompletedNCT04309643
Start: 2020-06-09End: 2020-07-08Updated: 2020-07-16
Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects
CompletedNCT04743414
Start: 2021-03-02End: 2021-04-05Updated: 2021-04-08
Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects
CompletedNCT04843540
Start: 2021-05-19End: 2021-07-02Updated: 2021-07-20
A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers
CompletedNCT05192369
Start: 2022-01-04End: 2022-01-28Updated: 2022-03-04
Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects
CompletedNCT05467709
Start: 2022-06-21End: 2022-07-07Updated: 2022-07-20
Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
CompletedNCT05467722
Start: 2022-06-01End: 2022-09-21Updated: 2022-11-29
Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers
CompletedNCT05467696
Start: 2022-06-14End: 2022-07-01Updated: 2022-07-20
Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543
CompletedNCT05468749
Start: 2022-06-06End: 2022-10-27Updated: 2022-11-29
Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects
CompletedNCT05478772
Start: 2022-07-11End: 2022-08-12Updated: 2022-08-30
Phase 2
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
CompletedNCT03137381
Start: 2017-08-09End: 2019-07-08Updated: 2022-07-19
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
CompletedNCT03811912
Start: 2019-03-21End: 2019-11-21Updated: 2022-12-09
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Active, not recruitingNCT03898479
Start: 2019-04-04End: 2027-06-30Target: 1000Updated: 2025-10-22
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
CompletedNCT03941548
Start: 2019-05-24End: 2020-04-10Updated: 2023-04-05
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
CompletedNCT04784533
Start: 2021-02-26End: 2023-05-16Updated: 2024-10-09
Phase 3
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
CompletedNCT04518995
Start: 2020-11-23End: 2022-04-19Updated: 2023-05-03
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
CompletedNCT04797650
Start: 2021-06-10End: 2022-06-29Updated: 2023-07-03
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
CompletedNCT05041803
Start: 2021-10-19End: 2024-07-18Updated: 2025-11-21